BDTX Black Diamond Therapeutics, Inc.
Financings ·
The new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration.
We have not published a story on Black Diamond Therapeutics yet. When there is news, it will appear here.
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, which target families of oncogenic mutations that share a similar protein structure and selectivity profile. The company aims to treat genetically defined tumors, overcome resistance, minimize toxicity mediated by wild-type protein and reach central nervous system disease. Its lead program is silevertinib, formerly BDTX-1535, a brain-penetrant, fourth-generation EGFR MasterKey inhibitor. Silevertinib is in a Phase 2 trial in patients with EGFR mutant non-small cell lung cancer in both the frontline and recurrent settings, and the company plans a randomized Phase 2 trial in newly diagnosed patients with EGFR altered glioblastoma in the second quarter of 2026. The FDA granted silevertinib Fast Track designation for EGFR mutant C797S-positive non-small cell lung cancer whose disease progressed on or after a third-generation EGFR TKI. The pipeline also includes an outlicensed clinical-stage product candidate and one development-stage candidate. The company works with Guardant Health on real-world evidence for patients with non-classical EGFR mutations.
| Product or program | What it is | Stage |
|---|---|---|
| Silevertinib (formerly BDTX-1535) | Brain-penetrant fourth-generation EGFR MasterKey inhibitor for lung cancer and glioblastoma | Phase 2 in EGFR mutant NSCLC; Fast Track designation |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $33.6 million | $51.3 million |
| Net income (loss) | $22.4 million | -$69.7 million |
| Cash from operations | $29.6 million | -$62.3 million |
| Cash and equivalents | $21.0 million | $36.4 million |
| Short-term investments | $107.7 million | $62.1 million |
Our latest story on this, dated Nov 13, 2025: "Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM". The story links the filing or release it is based on. Read the story.
Black Diamond Therapeutics, Inc. trades under the ticker BDTX on NASDAQ.
Black Diamond Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Black Diamond Therapeutics, Inc. is 1701541. Its filings are on SEC EDGAR.
57,453,747 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Black Diamond Therapeutics, Inc. under United States.
Our directory classifies Black Diamond Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Black Diamond Therapeutics, Inc. is US09203E1055.
aibio.space lists Black Diamond Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, which target families of oncogenic mutations that share a similar protein structure and selectivity profile. The company aims to treat genetically defined tumors, overcome resistance, minimize toxicity mediated by wild-type protein and reach central nervous system disease.
Silevertinib (formerly BDTX-1535): Brain-penetrant fourth-generation EGFR MasterKey inhibitor for lung cancer and glioblastoma Stage: Phase 2 in EGFR mutant NSCLC; Fast Track designation.
Black Diamond Therapeutics, Inc. reported net income of $22.4 million for the fiscal year ended Dec 31, 2025, and generated $29.6 million of cash from operations, per its annual report to the SEC.
$33.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$110.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Black Diamond Therapeutics, dated Nov 13, 2025: "Black Diamond Therapeutics files $500,000,000 replacement shelf with $150,000,000 ATM". The new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration. Source.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio